UBS Group’s NRX Pharmaceuticals Warrant NRXPW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $0 | Sell |
13
-1,839
| -99% | -$80 | ﹤0.01% | 10958 |
|
|
2025
Q4 | $131 | Buy |
1,852
+1,834
| +10,189% | +$183 | ﹤0.01% | 10156 |
|
|
2025
Q3 | $1 | Sell |
18
-1,482
| -99% | -$126 | ﹤0.01% | 10269 |
|
|
2025
Q2 | $128 | Buy |
1,500
+468
| +45% | +$38 | ﹤0.01% | 9978 |
|
|
2025
Q1 | $73 | Sell |
1,032
-2,879
| -74% | -$503 | ﹤0.01% | 9983 |
|
|
2024
Q4 | $501 | Sell |
3,911
-11,340
| -74% | -$704 | ﹤0.01% | 9444 |
|
|
2024
Q3 | $686 | Sell |
15,251
-8,230
| -35% | -$607 | ﹤0.01% | 8847 |
|
|
2024
Q2 | $1.41K | Buy |
23,481
+23,412
| +33,930% | +$2.94K | ﹤0.01% | 8581 |
|
|
2024
Q1 | $13 | Buy |
+69
| New | +$10 | ﹤0.01% | 9068 |
|
|
2023
Q4 | – | Sell |
-7,812
| Closed | -$625 | – | 9716 |
|
|
2023
Q3 | $625 | Buy |
+7,812
| New | +$1.23K | ﹤0.01% | 8368 |
|
|
2023
Q2 | – | Sell |
-3,356
| Closed | -$604 | – | 9408 |
|
|
2023
Q1 | $604 | Buy |
+3,356
| New | +$1.07K | ﹤0.01% | 8959 |
|
|
2022
Q3 | – | Sell |
-186
| Closed | – | – | 10729 |
|
|
2022
Q2 | $0 | Buy |
+186
| New | +$91 | ﹤0.01% | 10721 |
|
|
2022
Q1 | – | Sell |
-4,358
| Closed | -$8K | – | 10688 |
|
|
2021
Q4 | $8K | Buy |
4,358
+1,985
| +84% | +$6.28K | ﹤0.01% | 9046 |
|
|
2021
Q3 | $11K | Buy |
+2,373
| New | +$14.6K | ﹤0.01% | 7896 |
|
|
2020
Q4 | – | Sell |
-3,475
| Closed | -$1K | – | 8623 |
|
|
2020
Q3 | $1K | Buy |
+3,475
| New | +$923 | ﹤0.01% | 7814 |
|
|
2020
Q2 | – | Sell |
-6,100
| Closed | – | – | 8224 |
|
|
2020
Q1 | $0 | Buy |
6,100
+500
| +9% | +$60 | ﹤0.01% | 8252 |
|
|
2019
Q4 | $1K | Buy |
5,600
+500
| +10% | +$91 | ﹤0.01% | 7965 |
|
|
2019
Q3 | $1K | Hold |
5,100
| – | – | ﹤0.01% | 7845 |
|
|
2019
Q2 | $1K | Hold |
5,100
| – | – | ﹤0.01% | 7725 |
|
|
2019
Q1 | $1K | Hold |
5,100
| – | – | ﹤0.01% | 7551 |
|
|
2018
Q4 | $2K | Buy |
+5,100
| New | +$1.77K | ﹤0.01% | 7803 |
|
|
2018
Q3 | – | Sell |
-800
| Closed | – | – | 8159 |
|
|
2018
Q2 | $0 | Buy |
+800
| New | +$366 | ﹤0.01% | 8163 |
|
|
2018
Q1 | – | Sell |
-995
| Closed | – | – | 8052 |
|
|
2017
Q4 | $0 | Buy |
+995
| New | +$379 | ﹤0.01% | 8007 |
|
Other funds holding NRXPW
UBS Group's NRXPW Position: Q1 2026 in Review
UBS Group reduced its NRX Pharmaceuticals Warrant (NRXPW) stake by 99% in Q1 2026, selling an estimated $80 and leaving 13 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #10958.
UBS Group first reported a position in NRXPW in Q4 2017 and has held it in 23 quarters since. The position peaked at $11K in Q3 2021. 2 funds tracked by Wall St. Rank hold NRXPW as of Q1 2026.
- UBS Group held 13 shares of NRX Pharmaceuticals Warrant worth $0 as of Q1 2026.
- UBS Group sold 1,839 NRX Pharmaceuticals Warrant shares in Q1 2026, an estimated $80.
- NRX Pharmaceuticals Warrant made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10958 holding.
- UBS Group first reported a position in NRX Pharmaceuticals Warrant in Q4 2017 and has held it in 23 quarters since.
- UBS Group's NRX Pharmaceuticals Warrant position peaked at $11K in Q3 2021.
- 2 funds tracked by Wall St. Rank held NRX Pharmaceuticals Warrant as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.